English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Serum S100B represents a new biomarker for mood disorders

Schroeter, M. L., Sacher, J., Steiner, J., Schönknecht, P., & Mueller, K. (2013). Serum S100B represents a new biomarker for mood disorders. Current Drug Targets, 14(11), 1237-1248. doi:10.2174/13894501113149990014.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0014-5F63-7 Version Permalink: http://hdl.handle.net/21.11116/0000-0003-8452-B
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Schroeter, Matthias L.1, 2, 3, 4, Author              
Sacher, Julia1, 2, Author              
Steiner, Johann5, Author
Schönknecht, Peter5, 6, Author
Mueller, Karsten7, Author              
Affiliations:
1Clinic for Cognitive Neurology, University of Leipzig, Germany, ou_persistent22              
2Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society, ou_634549              
3Leipzig Research Center for Civilization Diseases (LIFE), University of Leipzig, Germany, ou_persistent22              
4German Consortium for Frontotemporal Lobar Degeneration (FTLD), Bonn, Germany, ou_persistent22              
5Department of Psychiatry, Otto von Guericke University Magdeburg, Germany, ou_persistent22              
6Department of Psychiatry and Psychotherapy, University of Leipzig, Germany, ou_persistent22              
7Methods and Development Unit Nuclear Magnetic Resonance, MPI for Human Cognitive and Brain Sciences, Max Planck Society, ou_634558              

Content

show
hide
Free keywords: Astrocytes; Bipolar disorder; DTI; Glia; Imaging; Major depression; Mania; Mood disorder; MRI; Oligodendrocytes; S100B
 Abstract: Recently, mood disorders have been discussed to be characterized by glial pathology. The protein S100B, a growth and differentiation factor, is located in, and may actively be released by astro- and oligodendrocytes. This protein is easily assessed in human serum and provides a useful parameter for glial activation or injury. Here, we review studies investigating the glial marker S100B in serum of patients with mood disorders. Studies consistently show that S100B is elevated in mood disorders; more strongly in major depressive than bipolar disorder. Consistent with the glial hypothesis of mood disorders, serum S100B levels interact with age with higher levels in elderly depressed subjects. Successful antidepressive treatment has been associated with serum S100B reduction in major depression, whereas there is no evidence of treatment effects in mania. In contrast to the glial marker S100B, the neuronal marker protein neuron-specific enolase is unaltered in mood disorders. Recently, serum S100B has been linked to specific imaging parameters in the human white matter suggesting a role for S100B as an oligodendrocytic marker protein. In sum, serum S100B can be regarded as a promising in vivo biomarker for mood disorders deepening the understanding of the pathogenesis and plasticity-changes in these disorders. Future longitudinal studies combining serum S100B with other cell-specific serum parameters and multimodal imaging are warranted to further explore this serum protein in the development, monitoring and treatment of mood disorders.

Details

show
hide
Language(s): eng - English
 Dates: 2013-03-262013-02-042013-05-172013-10
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: Peer
 Identifiers: DOI: 10.2174/13894501113149990014
PMID: 23701298
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Current Drug Targets
  Abbreviation : Curr Drug Targets
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Hilversum, Netherlands : Bentham Science Publishers
Pages: - Volume / Issue: 14 (11) Sequence Number: - Start / End Page: 1237 - 1248 Identifier: Other: 1389-4501
CoNE: /journals/resource/13894501